Open Access

Interleukin‑35 is associated with the tumorigenesis and progression of prostate cancer

  • Authors:
    • Jialin Zhu
    • Xueling Yang
    • Yan Wang
    • Haonan Zhang
    • Zhi Guo
  • View Affiliations

  • Published online on: April 3, 2019     https://doi.org/10.3892/ol.2019.10208
  • Pages: 5094-5102
  • Copyright: © Zhu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Interleukin (IL)‑35 is a novel member of the IL‑12 cytokine family, which exhibits a unique immune regulatory function. Previously, it was demonstrated that IL‑35 expression is significantly increased in a wide range of tumor tissues, promoting angiogenesis and inhibiting the anti‑tumor immune response. In the present study, the IL‑35 protein expression levels were measured in the plasma and tumor tissue of patients with prostate cancer (PCA), and its role was determined in the occurrence and progression of PCA. Plasma IL‑35 expression levels were measured using ELISA, and the associations of plasma IL‑35 and clinicopathological parameters were analyzed. Receiver operating characteristic curves were plotted to analyze the role of IL‑35 as a clinical biomarker for the diagnosis of PCA. Survival curve analysis demonstrated a significant decrease in the survival time in months in patients with PCA and increased expression levels of IL‑35 compared with the participants with relatively lower IL‑35 protein expression levels. IL‑35 expression was detected using immunohistochemical staining of a human PCA tissue microarray. Plasma IL‑35 expression levels in the patients with PCA were significantly increased compared with the patients with benign prostatic hyperplasia and the healthy controls. An increase in the plasma concentration of IL‑35 was associated with progression of PCA stage and an increase in the Gleason score. Significant differences in AUCs for IL‑35 and prostate‑specific antigen were observed with regard to the presence of lymph node and distant metastases in patients with PCA. The expression levels of Epstein‑barr virus‑induced gene 3 (EBI3) and IL‑12A (p35; the subunits which together form IL‑35) were significantly increased in the tumor tissue compared with the adjacent normal tissue. An association was identified between the Gleason score and the expression of EBI3 and p35. Therefore, increased expression of IL‑35 in the plasma and tumor tissues may contribute to the progression and metastasis of PCA, and IL‑35 may serve as a novel prognostic biomarker or therapeutic target for the treatment of PCA.
View Figures
View References

Related Articles

Journal Cover

June-2019
Volume 17 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
APA
Zhu, J., Yang, X., Wang, Y., Zhang, H., & Guo, Z. (2019). Interleukin‑35 is associated with the tumorigenesis and progression of prostate cancer. Oncology Letters, 17, 5094-5102. https://doi.org/10.3892/ol.2019.10208
MLA
Zhu, J., Yang, X., Wang, Y., Zhang, H., Guo, Z."Interleukin‑35 is associated with the tumorigenesis and progression of prostate cancer". Oncology Letters 17.6 (2019): 5094-5102.
Chicago
Zhu, J., Yang, X., Wang, Y., Zhang, H., Guo, Z."Interleukin‑35 is associated with the tumorigenesis and progression of prostate cancer". Oncology Letters 17, no. 6 (2019): 5094-5102. https://doi.org/10.3892/ol.2019.10208